# US 11,027,003 B2 · HLA-DR-binding antigen peptide derived from WT1

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 11,027,003 B2
- Document ID: US11027003B2
- Status: Granted
- Kind: B2
- Application number: 15/920,121
- Filed: 2018-03-13
- Published: 2018-07-26
- Granted: 2021-06-08
- Earliest claimed: 2003-11-05
- Assignees: International Institute of Cancer Immunology, Inc.
- Applicants: International Institute of Cancer Immunology, Inc.
- Inventors: Haruo Sugiyama
- Web page: https://patentgrep.com/patent/US11027003B2

## CPC

- C07K 14/4748: {Tumour specific antigens; Tumour rejection antigen precursors [TRAP], e.g. MAGE}
- A61K 39/0011: {Cancer antigens}
- A61K 39/001153: {Wilms tumor 1 [WT1]}
- A61P 35/00: Antineoplastic agents
- A61P 37/04: Immunostimulants
- A61K 38/00: Medicinal preparations containing peptides (peptides containing beta-lactam rings A61K31/00; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, A61K31/00; ergot alkaloids of the cyclic peptide type A61K31/48; containing macromolecular compounds having statistically distributed amino acid units A61K31/74; medicinal preparations containing antigens or antibodies A61K39/00; medicinal preparations characterised by the non-active ingredients, e.g. peptides as drug carriers, A61K47/00)
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

The present invention provides a WT1-derived HLA-DRB1*0405-binding antigen peptide, a polynucleotide encoding said peptide, a helper T cell inducer comprising said peptide or polynucleotide, and the like. It is related to a partial peptide consisting of 10-25 contiguous amino acids in the amino acid sequence of human WT1 shown in SEQ ID NO: 1, which binds to HLA-DRB1*0405 and induces helper T cells, a polynucleotide encoding said peptide, or a helper T cell inducer comprising said peptide or polynucleotide.

## Claims

### Claim 1

A peptide consisting of the amino acid sequence of SEQ ID NO: 24.

### Claim 2 (depends on 1)

A pharmaceutical composition which comprises the peptide according to claim 1 and a pharmaceutically acceptable carrier.

### Claim 3 (depends on 2)

The pharmaceutical composition of claim 2, which is an inducer of helper T cells.

### Claim 4 (depends on 1)

A pharmaceutical composition which comprises the peptide according to claim 1 in combination with a cancer antigen peptide set forth in any one of SEQ ID NO: 27 to 45.

### Claim 5 (depends on 1)

A kit, which comprises the peptide of claim 1, in combination with a cancer antigen peptide set forth in any one of SEQ ID NO: 27 to 25 and a pharmaceutically acceptable carrier.